Drain fluid may hold key to immunotherapy response in gastroesophageal cancer
NCT ID NCT05338060
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study collected surgical drain fluid and blood from 10 patients who had surgery for stomach or esophageal cancer. Researchers analyzed these samples for molecular markers that might predict how well a patient would respond to immunotherapy. The goal was to establish a method for collecting and studying these fluids, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help identify which patients with gastroesophageal cancer are most likely to benefit from immunotherapy after surgery.
What could go wrong
This was a very small, early study (10 participants) focused on collecting samples, not testing a treatment. The findings may not lead to a usable test or apply to larger populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Inova Schar Cancer Institute
Fairfax, Virginia, 22031, United States